Soleno Therapeutics (BST:6XC1) - Prezzo delle azioni, notizie e analisi

6XC1 Panoramica delle azioni

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Maggiori dettagli

6XC1 analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Le azioni sono altamente illiquide

Non ha una capitalizzazione di mercato significativa ( €23M )

+ 1 più rischio

Soleno Therapeutics, Inc. Concorrenti

Medigene

XTRA:MDG1

€20.6m

4SC

DB:VSC

€51.9m

2invest

XTRA:2INV

€63.2m

co.don

XTRA:CNW

€6.5m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Soleno Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.17
Massimo di 52 settimane	US$0.77
Minimo di 52 settimane	US$0.16
Beta	0.24
1Variazione di 1 mese	0%
Variazione a 3 mesi	n/a
Variazione di 1 anno	-77.36%
3Variazione a 3 anni	n/a
Variazione a 5 anni	-88.30%
Variazione dall'IPO	-99.33%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	6XC1	DE Biotechs	DE Mercato
7D	0%	-0.2%	0.8%
1Y	-77.4%	-16.9%	9.1%

Ritorno vs Industria: 6XC1 ha avuto una performance inferiore rispetto al German Biotechs che ha registrato un rendimento -16.9 % nell'ultimo anno.

Rendimento vs Mercato: 6XC1 ha avuto una performance inferiore al mercato German che ha registrato un rendimento 9.1 % nell'ultimo anno.

Volatilità dei prezzi

Is 6XC1's price volatile compared to industry and market?
6XC1 volatility
6XC1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: 6XC1 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di 6XC1 nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1999	20	Anish Bhatnagar	soleno.life

Soleno Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Soleno Therapeutics con la sua capitalizzazione di mercato?
6XC1 statistiche fondamentali
Capitalizzazione di mercato	€22.99m
Guadagni(TTM)	-€23.01m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.0x

Rapporto P/E

6XC1 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
6XC1 Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$23.42m
Guadagni	-US$23.42m

Ultimi guadagni dichiarati

Jun 30, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.19
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato 6XC1 nel lungo periodo?

Vedi performance storica e confronto

6XC1 Panoramica delle azioni

Analisi del rischio

Soleno Therapeutics, Inc. Concorrenti

XTRA:MDG1

€20.6m

DB:VSC

€51.9m

XTRA:2INV

€63.2m

XTRA:CNW

€6.5m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Recent updates

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome